Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells

被引:59
|
作者
Nishizaki, M
Sasaki, J
Fang, BL
Atkinson, EN
Minna, JD
Roth, JA
Ji, L
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Unit 445, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA
[3] Univ Texas, SW Med Ctr, Dept Internal Med & Pharmacol, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75230 USA
关键词
D O I
10.1158/0008-5472.CAN-04-0195
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aberrations of the tumor suppressor genes FHIT and p53 are frequently associated with a wide range of human cancers, including lung cancer. We studied the combined effects of FHIT and p53 proteins on tumor cell proliferation and apoptosis in human non-small cell lung carcinoma (NSCLC) cells in vitro and on tumor growth in animal models by adenoviral vector-mediated cotransfer of wild-type FHIT and p53 genes. We found that the coexpression of FHIT and p53 synergistically inhibited tumor cell proliferation in NSCLC cells in vitro and suppressed the growth of human tumor xenografts in nude mice. Furthermore, we found that this synergistic inhibition of tumor cell growth corresponded with the FHIT-mediated inactivation of MDM2, which thereby blocked the association of MDM2 with p53, thus stabilizing the p53 protein. Our results therefore reveal a novel molecular mechanism consisting of FHIT-mediated tumor suppression and the interaction of FHIT with other cellular components in the pathways regulating p53 activity. These findings show that combination treatment with synergistic tumor-suppressing gene therapy such as Ad-FHIT and Ad-p53 may be an effective therapeutic strategy for NSCLC and other cancers.
引用
收藏
页码:5745 / 5752
页数:8
相关论文
共 50 条
  • [41] A study of smoking, p53 tumor suppressor gene alterations and non-small cell lung cancer
    Tammemagi, MC
    McLaughlin, JR
    Mullen, JBM
    Bull, SB
    Johnston, MR
    Tsao, MS
    Casson, AG
    ANNALS OF EPIDEMIOLOGY, 2000, 10 (03) : 176 - 185
  • [42] Association of allelic loss at the FHIT locus and p53 alterations with tumour kinetics and chromosomal instability in non-small cell lung carcinomas (NSCLCs)
    Garinis, GA
    Gorgoulis, VG
    Mariatos, G
    Zacharatos, P
    Kotsinas, A
    Liloglou, T
    Foukas, P
    Kanavaros, P
    Kastrinakis, NG
    Vassilakopoulos, T
    Vogiatzi, T
    Field, JK
    Kittas, C
    JOURNAL OF PATHOLOGY, 2001, 193 (01): : 55 - 65
  • [43] Association of p53 codon 72 and MDM2 SNP309 polymorphisms with clinical outcome of advanced non-small cell lung cancer
    Han, Ji-Youn
    Lee, Geon Kook
    Jang, Dae Ho
    Lee, Sung Young
    Kim, Heung Tae
    Lee, Jin Soo
    CANCER RESEARCH, 2008, 68 (09)
  • [44] P53 codon 72 polymorphism increases the risk of somatic P53 gene mutations in non-small cell lung cancer (NSCLC)
    Szymanowska, A
    Jassem, E
    Dziadziuszko, R
    Borg, A
    Limon, J
    Kobierska-Gulida, G
    Skokowski, J
    Jassem, J
    LUNG CANCER, 2005, 49 : S75 - S75
  • [45] Prognostic role of p53 in stage III non-small cell lung cancer
    Berghmans, T
    Mascaux, C
    Martin, B
    Ninane, V
    Sculier, JP
    ANTICANCER RESEARCH, 2005, 25 (3C) : 2385 - 2389
  • [46] Relation between P53 codon 72 polymorphism and somatic P53 gene mutation in non-small cell lung cancer (NSCLC)
    Jassem, J.
    Szymanowska, A.
    Jassem, E.
    Dziadziuszko, R.
    Borg, A.
    Limon, J.
    Kobierska-Gulida, G.
    Skokowski, J.
    EJC SUPPLEMENTS, 2005, 3 (02): : 336 - 336
  • [47] p53 and angiogenesis in non-small-cell lung cancer
    Giatromanolaki, A
    Koukourakis, MI
    BRITISH JOURNAL OF CANCER, 1998, 77 (05) : 850 - 851
  • [48] P53 IN NON-SMALL-CELL LUNG-CANCER
    PASSLICK, B
    IZBICKI, JR
    RIETHMULLER, G
    PANTEL, K
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (10) : 801 - 802
  • [49] p53 and angiogenesis in non-small-cell lung cancer
    A Giatromanolaki
    MI Koukourakis
    British Journal of Cancer, 1998, 77 : 850 - 851
  • [50] Prognostic value of p53 abnormalities in non-small cell lung cancer (NSCLC)
    Niklinski, J
    Chyczewski, L
    Niklinska, W
    Laudanski, J
    Furman, M
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S248 - S248